Irritable bowel syndrome clinical trials

Explore recruiting irritable bowel syndrome clinical trials.

Recruiting irritable bowel syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Irritable bowel syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Mesotherapy treatment of irritable bowel syndrome

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptoms

Denmark

Human Pharmacology (Phase I)- Other EU CTIS Study details

Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome

Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A double-blind, randomized, placebo-controlled, multicenter trial evaluating the efficacy and safety of Saccharomyces boulardii CNCM I-745 in adult patients with non-constipated Irritable Bowel Syndrome.

Portugal, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Irritable bowel syndrome trials by city

Irritable bowel syndrome in Toronto Irritable bowel syndrome in Vancouver Irritable bowel syndrome in Montreal Irritable bowel syndrome in Calgary Irritable bowel syndrome in Edmonton Irritable bowel syndrome in Ottawa Irritable bowel syndrome in Winnipeg Irritable bowel syndrome in Quebec City Irritable bowel syndrome in Hamilton Irritable bowel syndrome in Kitchener Irritable bowel syndrome in London Irritable bowel syndrome in Halifax Irritable bowel syndrome in New York Irritable bowel syndrome in Los Angeles Irritable bowel syndrome in Chicago Irritable bowel syndrome in Houston

Other conditions

Postpartum depression Alcohol use disorder Substance use disorder COPD Asthma Long COVID Cystic fibrosis Pulmonary fibrosis Sleep apnea Chronic cough Crohn's disease Ulcerative colitis Celiac disease GERD Eosinophilic esophagitis Gastroparesis Rheumatoid arthritis Lupus Psoriatic arthritis Ankylosing spondylitis Osteoarthritis Knee osteoarthritis Osteoporosis Sjogren's syndrome